Collegium Pharmaceutical Closes New $980 Million Credit Facility

Collegium Pharmaceutical ( (COLL) ) has issued an update.

On December 30, 2025, Collegium Pharmaceutical announced the closing of its inaugural $980 million syndicated credit facility, a five-year financing maturing in 2030 that includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolving credit facility. The company used the initial term loan to fully repay approximately $581 million of principal outstanding under its prior $646 million term loan from funds managed by Pharmakon Advisors and expects the new SOFR-based facility, priced at a spread tied to its first lien net leverage ratio, to significantly lower its interest costs and generate meaningful annualized savings. With the delayed draw term loan and revolver undrawn at closing and earmarked for general corporate purposes and potential business development, the transaction strengthens Collegium’s capital structure, enhances financial flexibility and supports its strategy to drive long-term value through portfolio expansion and diversification.

The most recent analyst rating on (COLL) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Spark’s Take on COLL Stock

According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.

Collegium Pharmaceutical’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. While technical indicators show bullish momentum, valuation concerns and high leverage pose risks. The company’s strategic focus on growth and capital deployment supports a favorable outlook.

To see Spark’s full report on COLL stock, click here.

More about Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., based in Stoughton, Massachusetts, is a diversified biopharmaceutical company focused on improving the lives of people with serious medical conditions. The company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business centered on Jornay PM, a differentiated treatment for ADHD that serves as its primary growth driver, while pursuing disciplined capital deployment to expand and diversify its commercial portfolio.

Average Trading Volume: 477,864

Technical Sentiment Signal: Buy

Current Market Cap: $1.58B

Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.